Continuation vs Discontinuation of RAS Inhibitors in Patients Admitted With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Continuation Versus Discontinuation of Renin-Angiotensin System Inhibitors in Patients Admitted to Hospital With COVID-19: A Prospective, Randomised, Open-Label Trial
Lancet Respir Med 2021 Jan 07;[EPub Ahead of Print], JB Cohen, TC Hanff, P William, N Sweitzer, NR Rosado-Santander, C Medina, JE Rodriguez-Mori, N Renna, TI Chang, V Corrales-Medina, JF Andrade-Villanueva, A Barbagelata, R Cristodulo-Cortez, OA Díaz-Cucho, J Spaak, CE Alfonso, R Valdivia-Vega, M Villavicencio-Carranza, RJ Ayala-García, CA Castro-Callirgos, LA González-Hernández, EF Bernales-Salas, JC Coacalla-Guerra, CD Salinas-Herrera, L Nicolosi, M Basconcel, JB Byrd, T Sharkoski, LE Bendezú-Huasasquiche, J Chittams, DL Edmonston, CR Vasquez, JA ChirinosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.